Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhanced tumor control and survival in preclinical models with adoptive cell therapy preceded by low-dose radiotherapy.
Puebla-Osorio N, Fowlkes NW, Barsoumian HB, Xega K, Srivastava G, Kettlun-Leyton C, Nizzero S, Voss T, Riad TS, Wong C, Huang A, Hu Y, Mitchell J, Kim M, Rafiq Z, He K, Sezen D, Hsu E, Masrorpour F, Maleki A, Leuschner C, Cortez MA, Oertle P, Loparic M, Plodinec M, Markman JL, Welsh JW. Puebla-Osorio N, et al. Among authors: voss t. Front Oncol. 2024 Oct 9;14:1407143. doi: 10.3389/fonc.2024.1407143. eCollection 2024. Front Oncol. 2024. PMID: 39445067 Free PMC article.
Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3.
Hu Y, Paris S, Sahoo N, Wang Q, Wang Q, Barsoumian HB, Huang A, Da Silva J, Bienassis C, Leyton CSK, Voss TA, Masrorpour F, Riad T, Leuschner C, Puebla-Osorio N, Gandhi S, Nguyen QN, Wang J, Cortez MA, Welsh JW. Hu Y, et al. Among authors: voss ta. J Nanobiotechnology. 2024 Oct 1;22(1):597. doi: 10.1186/s12951-024-02855-0. J Nanobiotechnology. 2024. PMID: 39354474 Free PMC article.
Correction: Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafq Z, Riad TS, Hu Y, Huang A, Voss TA, Kettlun Leyton CS, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. He K, et al. Among authors: voss ta. J Exp Clin Cancer Res. 2024 Sep 10;43(1):256. doi: 10.1186/s13046-024-03183-9. J Exp Clin Cancer Res. 2024. PMID: 39256857 Free PMC article. No abstract available.
Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy.
He K, Puebla-Osorio N, Barsoumian HB, Sezen D, Rafiq Z, Riad TS, Hu Y, Huang A, Voss TA, Leyton CSK, Schuda LJ, Hsu E, Heiber J, Cortez MA, Welsh JW. He K, et al. Among authors: voss ta. J Exp Clin Cancer Res. 2024 Sep 2;43(1):251. doi: 10.1186/s13046-024-03165-x. J Exp Clin Cancer Res. 2024. PMID: 39218928 Free PMC article.
399 results